Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  primary central nervous system non-Hodgkin lymphoma
Stage/Subtype:  primary central nervous system non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 90 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB00001012, NCI-2013-00787, CR00022596, HEM-08059-LX, MR00041596, SOL-05025-L, MR00045915, SOL-05025-LM, OHSU-1012, OHSU-SOL-05025-L, NCT00293475
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, H-9936, NCT00671164, NCT00070226, 9936-ALCI, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Methoxyamine and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9483, NCI-2013-00877, P121184, 130118, 13-C-0118, NCT01851369
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH SCT 0813, CMH 13H11, NCT02053545
CD30 Receptor-Activated T-cells in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: LCCC1532-ATL, NCI-2016-00789, NCT02690545
A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 57643-101, NCI-2016-01069, NCT02711137
Lenalidomide, Combination Chemotherapy, and Rituximab in Treating Patients with Primary Effusion Lymphoma or KSHV-Associated Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0171, NCI-2016-01483, P162804, NCT02911142
Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 5F9003, NCI-2017-00032, NCT02953509
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTMX-M-072-001, NCI-2017-00275, NCT03013491
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMAK683X2101, NCI-2017-00635, 2016-001860-12, NCT02900651
A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPX-0005-01, NCI-2017-00648, NCT03093116
Methotrexate, Rituximab, Leucovorin Calcium, and Highly Active Antiretroviral Therapy in Treating Patients with AIDS-Related Primary Central Nervous System Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-C-0051, NCI-2013-01435, 339615, P6720, NCT00304044, 060051, NCT00267865
Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 25 and under
Trial IDs: MOHEL, NCI-2012-00807, H-8701, NCT00368355
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
Start Over